Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (95)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (4)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Myeloma (293)
  5. Survivorship Research (212)
  6. Hematologic Malignancies Research (209)

More Groups

People
  1. Neha Korde (188)
  2. Alexander Lesokhin (167)
  3. Hani Hassoun (160)
  4. Sergio Giralt (158)
  5. Malin Hultcrantz (155)
  6. Heather Landau (144)

More People

Years
  1. 2025 (9)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (95)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. JAMA Oncology (12)
  5. Blood Cancer Journal (11)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (105)
  2. Elsevier Inc. (70)
  3. Nature Publishing Group (25)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CAR T and CAR NK cells in multiple myeloma: Expanding the targets
    Review

    Shah, U. A.; Mailankody, S.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)
    Meeting Abstract

    Manasanch, E. E.; Jagannath, S.; Lee, H. C.; Patel, K. K.; Graham, C.; Kaufman, G. P.; Thomas, S. K.; Iyer, S.; Mailankody, S.; Korde, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Using current clinical markers to define high risk smoldering multiple myeloma: Agree to disagree
    Meeting Abstract

    Hill, E.; Korde, N.; Mailankody, S.; Morrison, C.; Dew, A.; Albert, J. H.; Graap, K.; Maura, F.; Landgren, O.; Kazandjian, D.
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • FDA analysis: Impact of body mass index (BMI) on outcomes in relapsed-refractory multiple myeloma
    Meeting Abstract

    Ershler, R.; Kanapuru, B.; Gong, Y.; Shah, U. A.; Mailankody, S.; Landgren, O.; Theoret, M.; Gormley, N. J.; Farrell, A. T.; Pazdur, R.
    Blood (2019)

    Fulltext@MSK | Save